Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CEACAM5

CEACAM5

Basics

Aliases:
This biomarker is also known as:
  • CEA,
  • DKFZp781M2392,
  • carcinoembryonic antigen-related cell adhesion molecule 5,
  • Meconium antigen 100,
  • CD66e,
  • CD66e Antigen,
  • Carcinoembryonic antigen,

View in BioMuta

Description…

From NCBI Gene: CEACAM5 is a member of the carcinoembryonic antigen (CEA) gene family, which belongs to the immunoglobulin superfamily. Two subgroups of the CEA family, the CEA cell adhesion molecules and the pregnancy-specific glycoproteins, are located within a 1.2 Mb cluster on the long arm of chromosome 19. Eleven pseudogenes of the CEA cell adhesion molecule subgroup are also found in the cluster. CEACAM5 is a cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. It is a receptor for E.coli Dr adhesins.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: CEACAM5

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Under Review

Overview

Levels of the four proteins (SLPI, TFPI, TFPI2, and TIMP1) were studied in a set of 12 late stage lung cancer serum samples and 12 normal serum samples using the immunoaffinity-MRM methodology. It was found that the immunoaffinity-mass spectrometry-based quantification approach provides a specific and accurate assay for verifying the expression of potential biomarkers in patient serum samples especially for those proteins for which the necessary reagents for ELISA development are unavailable. (From PMID:18388126)

Performance Comment

Researchers have developed an immunoaffinity-mass spectrometry-based approach using antibodies to enrich multiple proteins of interest from sera followed by LC-MRM-based quantification. As a proof of concept, it was demonstrated that CEA can be detected and quantified in a subset of patient sera. This is the first reported detection of CEA in sera using a mass spectrometry-based approach in serum samples. This method has allowed quantifying potential protein biomarkers in sera in the low ng/ml range with an acceptable CV. This approach was further applied to potential protein biomarkers discovered from tumor cell lines and tumor tissues. A linear response was obtained from a multiplex spiking experiment in normal human sera for secretory leukocyte peptidase inhibitor (4-500 ng/ml), tissue factor pathway inhibitor (TFPI) (42-1000 ng/ml), tissue factor pathway inhibitor 2 (TFPI2) (2-250 ng/ml), and metalloproteinase inhibitor 1 (TIMP1) (430-1000 ng/ml). (From PMID:18388126)

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

CEACAM5 is a member of the carcinoembryonic antigen (CEA) family. The carcinoembryonic proteins are found normally in the blood of a fetus. The CEA proteins are also found in the blood of some people who have certain types of tumors, such as colorectal, pancreas, breast, ovary, or lung. CEA levels are not usually elevated in early cancer, and in some cancers are not elevated at all.

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.